U.S. GLP-1 Prescriptions Jump 4-Fold as Obesity Rate Slips to 41%
Updated
Updated · Gizmodo · May 26
U.S. GLP-1 Prescriptions Jump 4-Fold as Obesity Rate Slips to 41%
2 articles · Updated · Gizmodo · May 26
EPIC Research data tracking more than 300 million patient records showed GLP-1 prescribing among U.S. adults rose to 8,819 per 100,000 patients in Q1 2026 from 1,884 in Q2 2021.
Over the same period, obesity in the dataset edged down to 41% from 42%, while the rate among people who had received a GLP-1 prescription fell more sharply to 69% from 75%.
The findings are not fully representative of the entire U.S., but they broadly match CDC estimates showing adult obesity near 40% and a reported decline between 2023 and 2024.
About 12% of Americans are currently taking a GLP-1 and 6% have stopped, with side effects, high prices and patchy insurance coverage still limiting wider use.
Cheaper semaglutide generics have been approved in countries including Canada and India, but they are unlikely to reach the U.S. for about five years.
GLP-1s are curbing obesity, but what happens to the $55 billion food industry when America's appetite changes for good?
Is a blockbuster drug the true cure for obesity, or does it mask the deeper societal issues driving the epidemic?
With U.S. generics delayed until the 2030s, how will millions afford these drugs once temporary Medicare programs end in 2027?
U.S. Adult Obesity Falls to 37% Amid GLP-1 Prescription Surge: Economic, Clinical, and Policy Implications
Overview
The report highlights a major shift in how adult obesity is managed in the U.S., driven by rising acceptance and use of GLP-1 receptor agonists. Recent surveys show that over a quarter of Americans now see GLP-1 drugs as a valid treatment for chronic obesity, with stigma around their use decreasing. This change in public opinion is matched by a surge in prescriptions, especially for drugs like tirzepatide. As more people view obesity as a complex medical issue rather than a personal failing, the growing use of GLP-1 medications is helping to reshape both treatment trends and societal attitudes.